Evidence map›Paper›PMID 39399463›Full record

ArticleFrontiers in pharmacology2024

Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway.

Dong Xie, Yulang Jiang, Huan Wang, Lingyi Zhu, Shuangqin Huang, Sheng Liu, Weihong Zhang, Tian Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dong Xie *Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Yulang Jiang *Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Huan Wang *Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Lingyi ZhuShanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Shuangqin HuangGeneral department, Songnan Town Community Health Service Center, Shanghai, China.
Sheng LiuShanghai University of Traditional Chinese Medicine, Shanghai, China.
Weihong ZhangShanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Tian LiShanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Triple-negative breast cancer (TNBC) is the most malignant type of breast cancer, and its prognosis is still the worst. It is necessary to constantly explore the pathogenesis and effective therapeutic targets of TNBC. Formononetin is an active ingredient with anti-tumor effects that we screened earlier. The main purpose of this study is to elucidate mechanism of the inhibitory effect of Formononetin on TNBC. Methods: We conducted experiments through both Results: In our study, Formononetin exhibits significant inhibitory effects on the proliferation of triple TNBC, both Discussion: In conclusion, this study provides evidence that Formononetin exerts an anti-proliferative effect on triple-negative breast cancer by inducing ferroptosis. Moreover, the mTORC1-SREBP1 signal axis is identified as the primary mechanism through which formononetin exerts its therapeutic effects. These findings suggest that formononetin holds promise as a potential targeted drug for clinical treatment of TNBC.

Indexed as

ferroptosisFormononetinmammalian target of rapamycin complex1sterol regulatory element-binding protein 1triple-negative breast cancer

Identifiers

PMID39399463
PMCPMC11470441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.